Last Updated : May 5, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Jemperli | dostarlimab | Endometrial cancer | Active | |||
Libtayo | cemiplimab | Locally advanced or metastatic NSCLC (first line) | Active | |||
Keytruda | pembrolizumab | Gastric or gastroesophageal junction adenocarcinoma | Active | |||
Keytruda | pembrolizumab | Biliary tract carcinoma | Active | |||
Doptelet | avatrombopag | Chronic immune thrombocytopenia (ITP) | Active | |||
TBC | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active | |||
Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Active | |||
Bimzelx | bimekizumab | Ankylosing spondylitis | Active | |||
Bimzelx | bimekizumab | Psoriatic arthritis | Active |